Detalhe da pesquisa
1.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706643
2.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Gynecol Oncol
; 166(1): 117-125, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35599167
3.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Proc Natl Acad Sci U S A
; 116(2): 619-624, 2019 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30584090
4.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Proc Natl Acad Sci U S A
; 116(45): 22730-22736, 2019 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31624127
5.
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Gynecol Oncol
; 163(2): 334-341, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452746
6.
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
Gynecol Oncol
; 158(3): 769-775, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32600791
7.
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Gynecol Oncol
; 156(2): 430-438, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31839338
8.
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Gynecol Oncol
; 155(1): 144-150, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31434613
9.
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Gynecol Oncol
; 153(1): 158-164, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30630630
10.
Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome.
Cell Rep
; 37(2): 109806, 2021 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34644561
11.
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
Oncotarget
; 11(5): 560-570, 2020 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32082489
12.
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Sci Rep
; 10(1): 973, 2020 01 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31969666
13.
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Mol Oncol
; 14(3): 645-656, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31891442
14.
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Front Oncol
; 10: 118, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32117765
15.
Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Clin Cancer Res
; 24(19): 4845-4853, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29941483